CMAX Clinical Research Pty Ltd

Running trials

• Not yet recruiting

  A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis

  NCT07904689· Phase 1· Source

• Enrolling by invitation

  To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants

  NCT07505030· Phase 1· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

  NCT07371455· Phase 1· Source

• Recruiting

  ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants

  NCT07334080· Phase 1· Source

• Recruiting

  Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis

  NCT06934252· Phase 1· Source

• Active, not recruiting

  Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007

  NCT06899230· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of NH280105 in Healthy Adult Participants

  NCT06870058· Phase 1· Source

• Terminated

  A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis

  NCT06681389· Phase 1· Source

• Completed

  A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of KIT2014 in Healthy Subjects

  NCT06659757· Phase 1· Source

• Completed

  Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults

  NCT05938946· Phase 1· Source

• Completed

  Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

  NCT05914909· Phase 1· Source